Privacy and Intellectual Property in the Age of Coronavirus
September 17, 2020
Institute for Privacy Protection and the Gibbons Institute of Law, Science & Technology.
The COVID-19 pandemic poses significant challenges to our privacy and intellectual property regimes. Seton Hall Law’s Institute for Privacy Protection and Gibbons Institute of Law, Science & Technology invite you to join panel discussions with legal academics, practitioners, and government officials to evaluate the impact of the COVID-19 pandemic on privacy and intellectual property. Efforts to contain the COVID-19 pandemic can impact privacy rights of patients, those at risk, and the general population. This panel will include topics addressing: What are the duties of healthcare providers to report patients' COVID-19 information? How should governments track infected individuals and others at high-risk? How secure are databases containing COVID-19 information? Patenting drugs and vaccines incentivizes innovation, but patents increase prices and affect availability. This panel will discuss the options of patenting COVID-19 drugs and vaccines as well as other alternatives pertinent in times of health emergencies, including compulsory licenses, voluntary licenses, and patent pools.To learn more about this event, Protecting Child Privacy Beyond The Information Age, click here.
The Gibbons Institute Mission
- SUPPORT FACULTY RESEARCH, investigation, analysis, discussion and scholarship that identifies and resolves societal tensions in the private and public sectors generated by technological innovation in the life sciences and technology industries.
- EDUCATE AND TRAIN law students, practicing attorneys and industry professionals to recognize and effectively address the complex legal issues they will encounter as practitioners and policy makers at the cross-section of law, technology and innovation.
- PROVIDE CONTINUING EDUCATION to the bench and bar regarding emerging issues and developments in intellectual property.
- COLLABORATE with leading health care and technology providers, and the life sciences industry, both public institutions and private businesses, to address these emerging challenges.